This Article Full Text Full Text (PDF) All Versions of this Article: 146/2/744    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Åkesson, L. Articles by Degerman, E. Search for Related Content PubMed PubMed Citation Articles by Åkesson, L. Articles by Degerman, E.

VPAC2-R Mediates the Lipolytic Effects of Pituitary Adenylate Cyclase-Activating Polypeptide/Vasoactive Intestinal Polypeptide in Primary Rat Adipocytes

Section for Molecular Signaling, Department of Cell and Molecular Biology (L.Å., G.E., E.D.), and Department of Medicine (B.A.), Lund University, SE-221 84 Lund, Sweden

Address all correspondence and requests for reprints to: Dr. Lina Åkesson, Biomedical Center C11, Lund University, SE-221 84 Lund, Sweden. E-mail: lina{at}akesson@.nu.

The neuropeptides pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) are structurally and functionally related. Their actions have been shown to be mediated by three different receptor subtypes: PAC1-R, which has exclusive affinity for PACAP, and VPAC1-R and VPAC2-R, which have equal affinity for PACAP and VIP. We recently showed that PACAP38 induces lipolysis in rat adipocytes, and in the present study we examined whether VIP has similar effects and which of the three receptors mediates this PACAP/VIP action. We showed by RT-PCR that all three receptor subtypes are present in rat adipocytes. We demonstrated that VIP (1–100 nM), like PACAP38, stimulates lipolysis in isolated adipocytes, as determined by glycerol release. By a pharmacological approach, using antagonists and agonists specific for the receptor subtypes, we elucidated the mechanisms by which PACAP38 and VIP mediate their lipolytic effects. We found that antagonists of PAC1-R [PACAP(6–38)] and VPAC1-R (PG97–269) did not affect lipolysis induced by 0.1–100 nM PACAP38 or VIP, and that a VPAC1-R agonist [K15, R16, L27VIP(1–7)GRF(8–27)] did not affect lipolysis at 1–1000 nM. However, two different VPAC2-R agonists [Hexa-VIP(1–28) and Ro25-1553] clearly mimicked the lipolytic effect of PACAP38 and VIP. In addition, the VPAC2-R antagonist PG99–465 (100 nM) caused right-shifted dose-response curves of PACAP38- and VIP-induced lipolysis. These results therefore provide evidence that all three PACAP/VIP receptor subtypes are expressed in primary rat adipocytes, but that the VPAC2-R subtype is responsible for mediating the lipolytic effects induced by PACAP38 and VIP.

This article has been cited by other articles:

				A. Giordano, C. Kay Song, R. R. Bowers, J. Christopher Ehlen, A. Frontini, S. Cinti, and T. J. Bartness Reply to Kreier and Buijs: no sympathy for the claim of parasympathetic innervation of white adipose tissue Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R550 - R552. [Full Text] [PDF]